Do analysts recommend HYPD or GDTC?

Hyperion DeFi currently has a consensus target price of $6.95, indicating a potential upside of 123.47%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Hyperion DeFi is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperion DeFi 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, HYPD or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Hyperion DeFi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperion DeFi $810K 58.21 -$45.31M -$9.95 N/A CytoMed Therapeutics $324.39K 35.60 -$3.10M N/A N/A

Is HYPD or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% CytoMed Therapeutics N/A N/A N/A

Do analysts recommend IZTC or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, IZTC or GDTC?

Invizyne Technologies has higher earnings, but lower revenue than CytoMed Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A CytoMed Therapeutics $324.39K 35.60 -$3.10M N/A N/A

Is IZTC or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A CytoMed Therapeutics N/A N/A N/A

Do analysts rate GDTC or ACTU?

Actuate Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 1,051.32%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation and earnings, GDTC or ACTU?

CytoMed Therapeutics has higher revenue and earnings than Actuate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $324.39K 35.60 -$3.10M N/A N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is GDTC or ACTU more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CytoMed Therapeutics N/A N/A N/A Actuate Therapeutics N/A -430.93% -180.86%

Do analysts rate MGX or GDTC?

Metagenomi currently has a consensus price target of $9.00, suggesting a potential upside of 614.29%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, MGX or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Metagenomi $25.21M 1.88 -$87.87M -$2.30 N/A CytoMed Therapeutics $324.39K 35.60 -$3.10M N/A N/A

Do analysts recommend APLM or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, APLM or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A CytoMed Therapeutics $324.39K 35.60 -$3.10M N/A N/A

Is APLM or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A CytoMed Therapeutics N/A N/A N/A

CytoMed Therapeutics (GDTC) Competitors

$0.98 +0.00 (+0.10%)

Closing price 07/2/2026 03:36 PM Eastern

Extended Trading

$0.98 0.00 (-0.10%)

As of 07/2/2026 05:35 PM Eastern

Compare

GDTC vs. HYPD, IZTC, ACTU, MGX, and APLM

Should you buy CytoMed Therapeutics stock or one of its competitors? MarketBeat compares CytoMed Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytoMed Therapeutics include Hyperion DeFi (HYPD), Invizyne Technologies (IZTC), Actuate Therapeutics (ACTU), Metagenomi (MGX), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry.

How does CytoMed Therapeutics compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hyperion DeFi currently has a consensus target price of $6.95, indicating a potential upside of 123.47%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Hyperion DeFi is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics has lower revenue, but higher earnings than Hyperion DeFi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A
CytoMed Therapeutics	$324.39K	35.60	-$3.10M	N/A	N/A

Hyperion DeFi has a beta of 2.49, meaning that its share price is 149% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

CytoMed Therapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
CytoMed Therapeutics	N/A	N/A	N/A

In the previous week, Hyperion DeFi had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for Hyperion DeFi and 0 mentions for CytoMed Therapeutics. Hyperion DeFi's average media sentiment score of 0.88 beat CytoMed Therapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Positive
CytoMed Therapeutics	Neutral

Summary

Hyperion DeFi beats CytoMed Therapeutics on 10 of the 13 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Invizyne Technologies has higher earnings, but lower revenue than CytoMed Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
CytoMed Therapeutics	$324.39K	35.60	-$3.10M	N/A	N/A

In the previous week, Invizyne Technologies' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Invizyne Technologies	Neutral
CytoMed Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

Summary

CytoMed Therapeutics beats Invizyne Technologies on 3 of the 3 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Actuate Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

0.0% of CytoMed Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, CytoMed Therapeutics' average media sentiment score of 0.00 equaled Actuate Therapeutics'average media sentiment score.

Company	Overall Sentiment
CytoMed Therapeutics	Neutral
Actuate Therapeutics	Neutral

Actuate Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 1,051.32%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

CytoMed Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Actuate Therapeutics	N/A	-430.93%	-180.86%

CytoMed Therapeutics has higher revenue and earnings than Actuate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$324.39K	35.60	-$3.10M	N/A	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

CytoMed Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Summary

CytoMed Therapeutics and Actuate Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, Metagenomi's average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
CytoMed Therapeutics	Neutral

CytoMed Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. CytoMed Therapeutics' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
CytoMed Therapeutics	N/A	N/A	N/A

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.88	-$87.87M	-$2.30	N/A
CytoMed Therapeutics	$324.39K	35.60	-$3.10M	N/A	N/A

Metagenomi currently has a consensus price target of $9.00, suggesting a potential upside of 614.29%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.0% of CytoMed Therapeutics shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Metagenomi has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Summary

Metagenomi beats CytoMed Therapeutics on 7 of the 13 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Apollomics had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for CytoMed Therapeutics. Apollomics' average media sentiment score of 0.59 beat CytoMed Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
CytoMed Therapeutics	Neutral

CytoMed Therapeutics has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
CytoMed Therapeutics	$324.39K	35.60	-$3.10M	N/A	N/A

Apollomics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

Summary

Apollomics beats CytoMed Therapeutics on 5 of the 7 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDTC vs. The Competition

Export

Metric	CytoMed Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.54M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.61	28.02	24.70
Price / Sales	35.60	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.17	8.66	10.96	6.46
Net Income	-$3.10M	$23.81M	$3.57B	$337.01M
7 Day Performance	-4.31%	3.39%	2.12%	1.69%
1 Month Performance	-24.34%	10.81%	5.25%	3.81%
1 Year Performance	-53.52%	62.61%	33.29%	23.90%

CytoMed Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDTC CytoMed Therapeutics	1.058 of 5 stars	$0.98 +0.1%	N/A	-53.5%	$11.54M	$324.39K	N/A	N/A	Gap Down
HYPD Hyperion DeFi	3.4216 of 5 stars	$3.07 +3.5%	$5.65 +84.3%	-80.5%	$46.47M	$810K	N/A	40	Positive News Analyst Forecast
IZTC Invizyne Technologies	N/A	$7.40 +3.6%	N/A	-13.0%	$46.27M	N/A	N/A	29	Gap Down
ACTU Actuate Therapeutics	1.8006 of 5 stars	$1.93 -1.5%	$17.50 +806.7%	-76.7%	$46.19M	N/A	N/A	10	Positive News
MGX Metagenomi	2.3722 of 5 stars	$1.23 +2.9%	$9.00 +634.7%	-23.8%	$46.12M	$25.21M	N/A	236

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. HYPD, IZTC, ACTU, MGX, and APLM

How does CytoMed Therapeutics compare to Hyperion DeFi?

Summary

How does CytoMed Therapeutics compare to Invizyne Technologies?

Summary

How does CytoMed Therapeutics compare to Actuate Therapeutics?

Summary

How does CytoMed Therapeutics compare to Metagenomi?

Summary

How does CytoMed Therapeutics compare to Apollomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. HYPD, IZTC, ACTU, MGX, and APLM

How does CytoMed Therapeutics compare to Hyperion DeFi?

Do insiders & institutionals have more ownership in HYPD or GDTC?

Do analysts recommend HYPD or GDTC?

Which has preferable valuation & earnings, HYPD or GDTC?

Which has more risk & volatility, HYPD or GDTC?

Is HYPD or GDTC more profitable?

Does the media refer more to HYPD or GDTC?

Summary

How does CytoMed Therapeutics compare to Invizyne Technologies?

Which has higher valuation & earnings, IZTC or GDTC?

Does the media prefer IZTC or GDTC?

Do analysts recommend IZTC or GDTC?

Do institutionals and insiders have more ownership in IZTC or GDTC?

Is IZTC or GDTC more profitable?

Summary

How does CytoMed Therapeutics compare to Actuate Therapeutics?

Do insiders and institutionals have more ownership in GDTC or ACTU?

Does the media favor GDTC or ACTU?

Do analysts rate GDTC or ACTU?

Is GDTC or ACTU more profitable?

Which has higher valuation and earnings, GDTC or ACTU?

Which has more risk and volatility, GDTC or ACTU?

Summary

How does CytoMed Therapeutics compare to Metagenomi?

Does the media favor MGX or GDTC?

Is MGX or GDTC more profitable?

Which has preferable earnings & valuation, MGX or GDTC?

Do analysts rate MGX or GDTC?

Do institutionals & insiders hold more shares of MGX or GDTC?

Which has more volatility and risk, MGX or GDTC?

Summary

How does CytoMed Therapeutics compare to Apollomics?

Do institutionals & insiders have more ownership in APLM or GDTC?

Do analysts recommend APLM or GDTC?

Does the media favor APLM or GDTC?

Which has preferable valuation & earnings, APLM or GDTC?

Which has more risk and volatility, APLM or GDTC?

Is APLM or GDTC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools